Growing community of inventors

Pasadena, CA, United States of America

Ron Diskin

Average Co-Inventor Count = 4.00

ph-index = 4

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 40

Ron DiskinMichel Nussenzweig (10 patents)Ron DiskinPamela J Bjorkman (10 patents)Ron DiskinJohannes Scheid (7 patents)Ron DiskinAnthony P West (3 patents)Ron DiskinRon Diskin (10 patents)Michel NussenzweigMichel Nussenzweig (32 patents)Pamela J BjorkmanPamela J Bjorkman (32 patents)Johannes ScheidJohannes Scheid (13 patents)Anthony P WestAnthony P West (3 patents)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. California Institute of Technology (10 from 4,548 patents)

2. The Rockefeller University (10 from 712 patents)


10 patents:

1. 12173052 - HIV-1 gp120 CD4 binding site antibodies targeting HIV escape mutants

2. 11634478 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof

3. 11472868 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

4. 11149081 - HIV-1 GP120 CD4 binding site antibodies targeting HIV escape mutants

5. 10889633 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof

6. 10590187 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with gp120

7. 9890207 - Highly active agonistic CD4 binding site anti-HIV antibodies (HAADS) comprising modified CDRH2 regions that improve contact with GP120

8. 9879068 - Antibodies targeting HIV escape mutants

9. 9783594 - Human immunodeficiency virus neutralizing antibodies and methods of use thereof

10. 9493549 - Antibodies directed toward the HIV-1 GP120 CD4 binding site with increased potency and breadth

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/9/2025
Loading…